Skip to main content

Research News

  • Biocartis and Fast-track diagnostics, have entered into a strategic collaboration to develop a range of multiplex infectious disease tests to run on the Biocartis Idylla system. As part of the collaboration, tests from Fast-track diagnostics’ comprehensive infectious disease menu will be developed for use on Biocartis’ innovative molecular diagnostics (MDx) platform, Idylla. Idylla is a fully-automated MDx system that delivers accurate, rapid tests in virtually any setting, from virtually any biological sample type, and without the need for pre-processing or specialist training.

  • Lemtrada (alemtuzumab), is new drug developed for treatment of Multiple Sclerosis (MS) reduces the relapse rates. Recently, Samuel F. Hunter, MD, PhD, President of the Advanced Neurosciences Institute in Franklin, Tennessee, presented a paper at the 2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers in Indianapolis, Indiana on outcomes in patients with relapsing multiple sclerosis treated with Lemtrada (alemtuzumab).

  • The Indian Council of Medical Research (ICMR) will soon start research on stillbirth to identify and understand the local causes and risk factors from the medical and sociological perspective. ICMR's initiative on stillbirth is significant as nearly 3 million third-trimester stillbirths occurring worldwide each year and 98 per cent of these occur in low-income and middle-income countries.  More than 1 million stillbirths occur in the intrapartum period, which can largely be prevented. The cause of stillbirth remains unidentified in India.

  • Using a partial synthetic process, by extracting trabectedin or ET-743, a compound found in marine invertebrate., scientists are producing a natural cancer drug. They are isolating the genetic blueprint of the ET-743's producer by using advanced sequencing techniques. The insights will make it possible for scientists to culture the bacteria in the laboratory without its host.

  • Like a dairy farmer tending to a herd of cows to produce milk, researchers are tending to colonies of the bacteria Escherichia coli (E. coli) to produce new forms of antibiotics — including three that show promise in fighting drug-resistant bacteria.

  • An international team including scientists from Albert Einstein College of Medicine of Yeshiva University and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) has identified the molecular “lock” that the deadly Ebola virus must pick to gain entry to cells. The findings, made in mice, suggest that drugs blocking entry to this lock could protect against Ebola infection.

  • The humble onion is proving its strength outside the culinary world, enabling scientists to develop artificial muscles by using gold-plated cells of the vegetable. Unlike previous artificial muscles, this one, created by a group of researchers from National Taiwan University, can either expand or contract to bend in different directions depending on the driving voltage applied.

  • An autonomous body under the AYUSH department of Union Health Ministry is planning to tieup with top homeopathy research organisations with an aim of boosting the healthcare industry. The Central Council for Research in Homeopathy (CCRH), the autonomous body under AYUSH, has called for further research to promote this system of medicine, said Dr R K Manchanda, Director General of CCRH.

Subscribe to Research News